Dtp Buis, C H van Werkhoven, M A van Agtmael, H I Bax, M Berrevoets, Mgj de Boer, Mjm Bonten, J E Bosmans, J Branger, S Douiyeb, Lbs Gelinck, E Jong, Ajj Lammers, Jtm Van der Meer, J J Oosterheert, E Sieswerda, R Soetekouw, J E Stalenhoef, T W Van der Vaart, E A Bij de Vaate, N J Verkaik, Mga Van Vonderen, P J De Vries, J M Prins, Kce Sigaloff
INTRODUCTION: A major knowledge gap in the treatment of complicated Staphylococcus aureus bacteraemia (SAB) is the optimal duration of antibiotic therapy. Safe shortening of antibiotic therapy has the potential to reduce adverse drug events, length of hospital stay and costs. The objective of the SAFE trial is to evaluate whether 4 weeks of antibiotic therapy is non-inferior to 6 weeks in patients with complicated SAB. METHODS AND ANALYSIS: The SAFE-trial is a multicentre, non-inferiority, open-label, parallel group, randomised controlled trial evaluating 4 versus 6 weeks of antibiotic therapy for complicated SAB...
April 21, 2023: BMJ Open